Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Breast Cancer Weekly Highlights | November 23–30, 2025
My personal selection of the most relevant scientific data published this week.
1. Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer
- TTNT 8.2m (1–2 prior lines); 10.8m when used earlier.
- Benefit maintained in visceral disease (7.9m) and fulvestrant-naïve (12.9m).
- ESR1 + PI3K-pathway mutations still benefited.
Clinical Cancer Research, 2025
2. Dynamic Tumor-Infiltrating Lymphocytes Predict Survival in HR+/HER2- Early Breast Cancer: A Pre-to-Post Neoadjuvant Chemotherapy Study
- Baseline TILs ≥10% = poorer prognosis.
- Post-NAC high TILs = worst outcomes (OS HR 2.82).
- Low→High = higher relapse; High→Low = improved survival.
Breast Cancer Research, 2025
3. Axillary Management in Breast Cancer Patients with Positive Nodes Following Neoadjuvant Chemotherapy
- In ypN+ after SLNB/TAD, 46.7% had additional disease in ALND.
- Key predictors: baseline node burden, extracapsular extension, SLN+ ratio ≥0.5.
Annals of Surgical Oncology, 2025
4. PROMENADE: Pembrolizumab for Early ER-Low/HER2-Negative Breast Cancer — Real-World French Cohort
- ER-low tumors showed pCR rates similar to TNBC.
- Supports IO-based strategies for ER 1–10%.
ESMO Open, 2025
5. Real-World Outcomes of Early-Stage HER2+ Patients Treated With Adjuvant Paclitaxel–Trastuzumab
- 3-year RFS 97.3%, DRFS 98.2%.
- Very low toxicity and discontinuation rates.
- Confirms TH (APT) as standard for small node-negative HER2+ tumors.
NPJ Breast Cancer, 2025
6. Early Tumor Volume Reduction by DCE-MRI Predicts pCR in TNBC Undergoing Neoadjuvant Therapy
- >80% reduction after 2 AC cycles predicts pCR.
- Promising for early response stratification.
NPJ Breast Cancer, 2025
7. Integrative Analysis of RNA Signatures and Recurrent Genomic Alterations Before Treatment
- Non-responders: high proliferation, protumor immune signatures, TP53/ESR1/RB1/FGFR2 alterations.
- Multiple genomic signatures associated with worse outcomes.
ESMO Open, 2025
8. Real-World Outcomes of Trastuzumab Deruxtecan in HR-Negative HER2-Low mBC
- ORR 35.9%, DCR 75%, median PFS 5.0m, OS 14.9m
- Safety consistent with known T-DXd profile.
NPJ Breast Cancer, 2025
9. Efficacy, Safety, and Predictive Biomarkers of Neoadjuvant Nab-Paclitaxel and Pembrolizumab in HR-Positive Breast Cancer — Randomized Pilot Trial
- pCR 17%, RCB 0–1 28%.
- Responses enriched in immune-activated tumors; estrogen-driven tumors less responsive.
Nature Communications, 2025
10. Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early HER2-Positive Breast Cancer — Phase II Trial
- Bispecific HER2-ADC with TOPO-I payload; 6 or 7.5 mg/kg × 6–8 cycles.
- pCR 58–77% (best 76.9%); HR– >90%.
- TRAEs 23–31%; one reversible ILD.
JCO, 2025.”
More posts featuring Benjamin Walbaum.
